Modality
Gene Therapy
MOA
KRASG12Di
Target
PD-1
Pathway
RNA Splicing
RBMeso
Development Pipeline
Preclinical
Nov 2017
→ Jan 2030
PreclinicalCurrent
NCT08413620
1,198 pts·RB
2023-03→2030-01·Terminated
NCT04863237
2,401 pts·RB
2017-11→2026-12·Not yet recruiting
3,599 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-269mo awayInterim· RB
2030-01-143.8y awayInterim· RB
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Not yet…
Preclinical
Termina…
Catalysts
Interim
2026-12-26 · 9mo away
RB
Interim
2030-01-14 · 3.8y away
RB
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08413620 | Preclinical | RB | Terminated | 1198 | PASI75 |
| NCT04863237 | Preclinical | RB | Not yet recr... | 2401 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |